The incidence of multi drug resistant tuberculosis among patients receiving standardized treatment regimen for suspected MDR-TB Source: Annual Congress 2012 - MDR- and XDR-TB: clinical and public health experiences Year: 2012
The relapses of tuberculosis with multiple drug resistance among patients treated under DOTS-Plus regimen Source: Annual Congress 2010 - Tuberculosis drug resistance Year: 2010
Treatment out-come in acquired drug resistance tuberculous patients receiving tailored regimen based on sensitivity report Source: Annual Congress 2008 - Outcomes of tuberculosis treatment Year: 2008
Secondary drug resistance during an intravenous intermittent chemotherapy in newly cases TB Source: Annual Congress 2011 - Epidemiology of multidrug-resistant and extensively drug-resistant tuberculosis Year: 2011
Factors affecting the efficacy of treatment of MDR/XDR TB patients receiving bedaquiline Source: International Congress 2019 – Tuberculosis: a public health approach Year: 2019
Efficacy of a standard chemotherapy regimen in the management of sputum-positive pulmonary TB relapses Source: Eur Respir J 2003; 22: Suppl. 45, 41s Year: 2003
Resistance of sputum nonspecific microflora in MDR TB patients treated with second-line anti-TB drugs Source: Eur Respir J 2002; 20: Suppl. 38, 614s Year: 2002
Efficiency of standard chemotherapy of patients with pulmonary TB with relapses and treatment failure at drug resistance of M. tuberculosis Source: Eur Respir J 2001; 18: Suppl. 33, 339s Year: 2001
Efficiency of treatment regimens for chronic tuberculosis patients Source: Eur Respir J 2003; 22: Suppl. 45, 519s Year: 2003
Efficiency of intravenous treatment with levofloxacin in patients with MDR pulmonary tuberculosis in the intensive phase of chemotherapy Source: Virtual Congress 2021 – The ongoing threat of drug-resistant tuberculosis Year: 2021
The assessment of the efficacy of a standard chemotherapy regimen in the treatment of new sputum-positive tuberculosis (TB) patients Source: Eur Respir J 2001; 18: Suppl. 33, 340s Year: 2001
Effectiveness of the intensive phase of chemotherapy in pulmonary TB patients with primary drug resistance Source: Eur Respir J 2006; 28: Suppl. 50, 290s Year: 2006
Clinical efficacy of new anti-TB drug ²tubelon² during complex chemotherapy in patients with first-time diagnosed destuctive pulmonary TB Source: Eur Respir J 2006; 28: Suppl. 50, 8s Year: 2006
Treatment outcomes of new cases of polyresistant pulmonary TB with second line anti-TB drugs in DOTS-Plus regimen Source: Eur Respir J 2002; 20: Suppl. 38, 359s Year: 2002
Efficacy of standard chemotherapy regimen in patients with newly detected sputum-positive destructive pulmonary tuberculosis Source: Eur Respir J 2003; 22: Suppl. 45, 40s Year: 2003
The efficacy of treatment of patients with drug resistant tuberculosis Source: Eur Respir J 2007; 30: Suppl. 51, 661s Year: 2007
Cost-effectiveness analysis of regimens chemotherapy in patients with multidrug resistant tuberculosis (MDR TB) compared with standard regimen in patients with susceptible MBT Source: Eur Respir J 2003; 22: Suppl. 45, 526s Year: 2003
The clinical value of intravenous pulse therapy in first retreatment pulmonary tuberculosis patients Source: Annual Congress 2009 - Treatment of tuberculosis at times of emerging drug resistance Year: 2009
Efficacy of intravenous administration of anti-tuberculosis drugs in patients with multidrug-resistant tuberculosis Source: Annual Congress 2013 –Drug-resistant tuberculosis Year: 2013
Features of intravenous anti TB therapy in patients with first diagnosed pulmonary TB in the intensive phase of treatment Source: International Congress 2017 – MDRTB: detection and management Year: 2017